Immunocore Holdings plc Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.87M, a 842.42% increase year-over-year.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $3.67M, a 1135.69% increase year-over-year.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $2.55M, a 51.06% decline year-over-year.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $198.00K, a 98.09% decline year-over-year.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for fiscal 2025 was $12.37M, a 97.43% increase from fiscal 2024.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for fiscal 2024 was $6.27M, a 81.76% decline from fiscal 2023.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for fiscal 2023 was $34.35M, a 254.23% increase from fiscal 2022.
- Immunocore Holdings plc stock issued during period, value, stock options exercised for fiscal 2022 was $9.70M, a 647.00% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $12.37M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $1.87M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $3.67M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $2.55M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $6.27M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $198.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $297.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $5.21M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $34.35M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $10.38M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $11.56M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $6.16M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $9.70M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $1.30M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |